Trial
NCT02278783
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Utah
Collaborators
Bayer
Condition
Ovarian Cancer
Intervention
regorafenib
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-06